Wade Hull
Chief Tech/Sci/R&D Officer presso CRESCITA THERAPEUTICS INC.
Patrimonio netto: 11 618 $ in data 29/02/2024
Profilo
Wade Hull is currently the Vice President-Research & Development at Nuvo Pharmaceuticals, Inc. and Crescita Therapeutics, Inc. He previously worked as the Principal at Utah Medical Products, Inc. and as the Vice President-Research & Development at ZARS Pharma, Inc. Mr. Hull completed his undergraduate and graduate degrees at the University of Utah.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
28/12/2023 | 39 384 ( 0.20% ) | 11 618 $ | 29/02/2024 |
Posizioni attive di Wade Hull
Società | Posizione | Inizio |
---|---|---|
CRESCITA THERAPEUTICS INC. | Chief Tech/Sci/R&D Officer | 01/03/2016 |
NUVO PHARMACEUTICALS INC. | Chief Tech/Sci/R&D Officer | - |
Precedenti posizioni note di Wade Hull
Società | Posizione | Fine |
---|---|---|
UTAH MEDICAL PRODUCTS, INC. | Corporate Officer/Principal | 01/12/1996 |
ZARS Pharma, Inc.
ZARS Pharma, Inc. Pharmaceuticals: MajorHealth Technology ZARS Pharma, Inc. develops and distributes drugs. It is a specialty pharmaceutical company focused on the development and commercialization of topically administered drugs, primarily for the treatment of pain, using its proprietary drug delivery technologies. The company was founded by Jie Zhang, Theodore H. Stanley, Larry D. Rigby and Michael A. Ashburn in 1996 and is headquartered in Salt Lake City, UT. | Chief Tech/Sci/R&D Officer | - |
Formazione di Wade Hull
University of Utah | Graduate Degree |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 2 |
---|---|
UTAH MEDICAL PRODUCTS, INC. | Health Technology |
CRESCITA THERAPEUTICS INC. | Health Technology |
Aziende private | 2 |
---|---|
ZARS Pharma, Inc.
ZARS Pharma, Inc. Pharmaceuticals: MajorHealth Technology ZARS Pharma, Inc. develops and distributes drugs. It is a specialty pharmaceutical company focused on the development and commercialization of topically administered drugs, primarily for the treatment of pain, using its proprietary drug delivery technologies. The company was founded by Jie Zhang, Theodore H. Stanley, Larry D. Rigby and Michael A. Ashburn in 1996 and is headquartered in Salt Lake City, UT. | Health Technology |
Nuvo Pharmaceuticals, Inc.
Nuvo Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Nuvo Pharmaceuticals, Inc. is a pharmaceutical company, which is engaged in developing innovative therapeutic pharmaceutical products. It operates through the following segments: Commercial Business, Production and Service Business, and Licensing and Royalty Business. The Commercial Business segment includes Blexten, Cambia, the canadian business for Resultz and Suvexx, and mature assets. The Production and Service Business segment supplies Pennsaid to Horizon for the U.S. market and is engaged in ongoing partnering efforts for Pennsaid. The Licensing and Royalty Business segment engages in the selling of Vimovo. The company was founded on August 22, 1983 and is headquartered in Mississauga, Canada. | Health Technology |
- Borsa valori
- Insiders
- Wade Hull